[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619669":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":40,"locations":50,"responsibleParty":134,"collaborators":136,"id":140,"slug":141,"hasResults":142,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":142,"sex":148,"minAge":149,"maxAge":25,"enrollmentInfo":150,"targetDuration":25,"studyType":153,"phases":154,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":163,"whyStopped":25,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":173},{"fullName":5,"class":6},"Xinqiao Hospital of Chongqing","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Eptifibatide (Integrilin)","EXPERIMENTAL","Participants randomized to this arm will receive intravenous eptifibatide (135 μg\u002Fkg bolus, followed by 0.75 μg\u002Fkg\u002Fmin infusion for 2 hours) initiated within 60 minutes after completion of standard intravenous thrombolysis (either alteplase or tenecteplase). Antiplatelet therapy with aspirin (100 mg) and\u002For clopidogrel (75 mg) will be administered at 24h after thrombolysis until the follow-up period of 90 days.",[13],"Drug: Eptifibatide (Integrilin)",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard Medical Therapy","ACTIVE_COMPARATOR","Participants randomized to this arm will not receive intravenous eptifibatide after completion of standard intravenous thrombolysis. Antiplatelet therapy with aspirin (100 mg) and\u002For clopidogrel (75 mg) will be administered at 24h after thrombolysis until the follow-up period of 90 days.",[19],"Drug: Standard Medical Therapy",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Participants will receive intravenous eptifibatide (135 μg\u002Fkg bolus, followed by 0.75 μg\u002Fkg\u002Fmin infusion for 2 hours) initiated within 60 minutes after completion of standard intravenous thrombolysis (either alteplase or tenecteplase). Antiplatelet therapy with aspirin (100 mg) and\u002For clopidogrel (75 mg) will be administered at 24h after thrombolysis until the follow-up period of 90 days.",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Participants will not receive intravenous eptifibatide after completion of standard intravenous thrombolysis. Antiplatelet therapy with aspirin (100 mg) and\u002For clopidogrel (75 mg) will be administered at 24h after thrombolysis until the follow-up period of 90 days.",[15],[30,34,37],{"name":31,"affiliation":32,"role":33},"Zhongming Qiu, MD","Xinqiao Hospital of the Army Medical University","PRINCIPAL_INVESTIGATOR",{"name":35,"affiliation":36,"role":33},"Zhenqiang Zhao, MD","The First Affiliated Hospital of Hainan Medical University",{"name":38,"affiliation":39,"role":33},"Daojun Hong, MD","The First Affiliated Hospital of Nanchang University",[41,46],{"name":42,"role":43,"phone":44,"phoneExt":25,"email":45},"Wei Li, MD","CONTACT","+86 18976574937","weiligysy@163.com",{"name":47,"role":43,"phone":48,"phoneExt":25,"email":49},"Jing Lin, MD","+86 15626456674","linjingsys2016@126.com",[51,69,83,98,108,122],{"facility":52,"status":25,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"Xinqiao Hospital and The Second Affiliated Hospital","Chongqing","Chongqing Municipality","400000","China","CN",{"type":59,"coordinates":60},"Point",[61,62],106.55771,29.56026,{"lat":62,"lon":61},[65],{"name":66,"role":43,"phone":67,"phoneExt":25,"email":68},"Zhongming Qiu","+86 13236599269","qiuzhongmingdoctor@163.com",{"facility":36,"status":25,"city":70,"state":71,"zip":72,"country":56,"countryCode":57,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Haikou","Hainan","570100",{"type":59,"coordinates":74},[75,76],110.34651,20.03421,{"lat":76,"lon":75},[79],{"name":80,"role":43,"phone":81,"phoneExt":25,"email":82},"Zhenqiang Zhao","+86 13976015677","zhenqiang.zhao@qq.com",{"facility":84,"status":25,"city":85,"state":86,"zip":87,"country":56,"countryCode":57,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"Ganzhou People's Hospital","Ganzhou","Jiangxi","341000",{"type":59,"coordinates":89},[90,91],114.9326,25.84664,{"lat":91,"lon":90},[94],{"name":95,"role":43,"phone":96,"phoneExt":25,"email":97},"Guoyong Zeng","+86 13507079530","hsyygy@163.com",{"facility":99,"status":25,"city":85,"state":86,"zip":87,"country":56,"countryCode":57,"cosmosGeoPoint":100,"geoPoint":102,"contacts":103},"The First Affiliated Hospital of Gannan Medical University",{"type":59,"coordinates":101},[90,91],{"lat":91,"lon":90},[104],{"name":105,"role":43,"phone":106,"phoneExt":25,"email":107},"Qiujiang Xi","+86 18170868978","Xiqiujiang992437@sina.com",{"facility":109,"status":25,"city":110,"state":86,"zip":111,"country":56,"countryCode":57,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"The Affiliated Hospital of Jinggangshan University","Ji’an","343000",{"type":59,"coordinates":113},[114,115],114.97927,27.11716,{"lat":115,"lon":114},[118],{"name":119,"role":43,"phone":120,"phoneExt":25,"email":121},"Yongcheng Zhang","+86 13970656839","2378666511@qq.com",{"facility":39,"status":25,"city":123,"state":86,"zip":124,"country":56,"countryCode":57,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"Nanchang","330006",{"type":59,"coordinates":126},[127,128],115.85306,28.68396,{"lat":128,"lon":127},[131],{"name":38,"role":43,"phone":132,"phoneExt":25,"email":133},"+86 13879187691","hongdaojun@hotmail.com",{"type":33,"investigatorFullName":66,"investigatorTitle":135,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Professor",[137,139],{"name":36,"class":138},"OTHER_GOV",{"name":39,"class":6},"100619669","phase-3-eptifibatide-for-extended-window-ischemic-stroke-after-thrombolysis-100619669",false,"NCT07347626","Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis","Efficacy and Safety of Eptifibatide Therapy Following Intravenous Thrombolysis in Acute Ischemic Stroke Patients Within 4.5 to 24 Hours After Onset: A Multicenter, Randomized Controlled Trial","E-TWIST","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Acute ischemic stroke, with the time interval from last known well to hospital presentation being 4.5 to 24 hours.\n3. NIHSS score ≥ 4 before randomization; if large or medium vessel occlusion is present, an NIHSS score ≤ 10 is also required.\n4. Presence of any of the following conditions after completion of standard intravenous thrombolysis:\n\n   1. No significant neurological improvement within 1 hour (defined as a change in NIHSS score ≤ 1 point from baseline).\n   2. Early neurological deterioration within 1 hour of onset (defined as an increase in NIHSS score ≥ 2 points from baseline).\n   3. Neurological fluctuation within 24 hours after symptom onset (defined as an increase in NIHSS score ≥ 2 points from the lowest value post-thrombolysis).\n5. Ability to receive the assigned study drug within 60 minutes after intravenous thrombolysis.\n6. Signed written informed consent obtained from the patient or their legal representative.\n\nExclusion Criteria:\n\n1. Intracranial hemorrhage confirmed by CT or MRI.\n2. Planned endovascular therapy.\n3. Presence of any definite cardioembolic source, including: chronic or paroxysmal atrial fibrillation, sick sinus syndrome, mitral stenosis, mechanical heart valve, endocarditis, intracardiac thrombus or vegetation, myocardial infarction within 3 months, dilated cardiomyopathy, spontaneous echo contrast in the left atrium, or ejection fraction \\\u003C 30%.\n4. Pre-stroke modified Rankin Scale (mRS) score ≥ 2.\n5. Renal insufficiency (glomerular filtration rate \\\u003C 30 ml\u002Fmin or serum creatinine \\> 220 μmol\u002FL \\[2.5 mg\u002FdL\\]).\n6. Known hypercoagulable state.\n7. Platelet count \\\u003C 100 × 10⁹\u002FL.\n8. Pregnancy or lactation.\n9. Allergy to eptifibatide, other glycoprotein IIb\u002FIIIa inhibitors, aspirin, or clopidogrel.\n10. History of non-atherosclerotic arteriopathy, including moyamoya disease, arterial dissection, or fibromuscular dysplasia.\n11. Pre-existing neurological or psychiatric disease that would preclude accurate neurological assessment.\n12. History of bleeding diathesis, severe cardiac disease, liver disease, or sepsis.\n13. Brain tumor with mass effect on imaging (except for small meningiomas).\n14. Evidence of intracranial arteriovenous malformation or aneurysm with diameter \\> 5 mm on CT or MR angiography.\n15. Current participation in another clinical trial.\n16. Any terminal illness with life expectancy \\\u003C 6 months.\n17. Anticipated inability to complete follow-up.","ALL","18 Years",{"count":151,"type":152},786,"ESTIMATED","INTERVENTIONAL",[155],"PHASE3","This is a multicenter, randomized, open-label, blinded-endpoint clinical trial designed to evaluate the efficacy and safety of early administration of eptifibatide following intravenous thrombolysis in patients with acute ischemic stroke who present 4.5 to 24 hours after symptom onset.",[158],"Acute Ischemic Stroke",[158,160,161,162],"Intravenous thrombolysis","Eptifibatide","Neurological deterioration","NOT_YET_RECRUITING","2026-01-15",{"date":166,"type":167},"2026-01-16","ACTUAL",{"date":169,"type":152},"2026-03-01",{"date":171,"type":152},"2029-12-31",{"name":5,"class":6},6]